A multicenter, randomised, open-label, three-parallel groups, phase 2-3 study to evaluate the efficacy and safety of masitinib with dexamethasone, gemcitabine with dexamethasone and the combination of masitinib, gemcitabine and dexamethasone in patients with relapsed or refractory peripheral T-cell lymphoma
Phase of Trial: Phase II/III
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs Masitinib (Primary) ; Dexamethasone; Gemcitabine
- Indications Peripheral T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 16 Jun 2018 This trial has been changed to Discontinued in Spain.
- 13 Jun 2018 This trial has been completed in Spain (End date: 2018-05-30).
- 25 May 2018 This trial has been Discontinued in Greece.